BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34475526)

  • 1. Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer.
    Nguyen HG; Lundström O; Blank A; Dawson H; Lugli A; Anisimova M; Zlobec I
    Mod Pathol; 2022 Feb; 35(2):240-248. PubMed ID: 34475526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype.
    Walsh MD; Clendenning M; Williamson E; Pearson SA; Walters RJ; Nagler B; Packenas D; Win AK; Hopper JL; Jenkins MA; Haydon AM; Rosty C; English DR; Giles GG; McGuckin MA; Young JP; Buchanan DD
    Mod Pathol; 2013 Dec; 26(12):1642-56. PubMed ID: 23807779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
    Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
    World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma.
    Imai Y; Yamagishi H; Fukuda K; Ono Y; Inoue T; Ueda Y
    World J Gastroenterol; 2013 Jul; 19(25):3957-68. PubMed ID: 23840140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
    Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
    Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients.
    van de Weerd S; Smit MA; Roelands J; Mesker WE; Bedognetti D; Kuppen PJK; Putter H; Tollenaar RAEM; Roodhart JML; Hendrickx W; Medema JP; van Krieken JHJM
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathological classification of colorectal cancer.
    Müller MF; Ibrahim AE; Arends MJ
    Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy.
    Chida K; Kawazoe A; Suzuki T; Kawazu M; Ueno T; Takenouchi K; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Kuwata T; Sakamoto N; Watanabe J; Mano H; Ikeda M; Shitara K; Endo I; Nakatsura T; Yoshino T
    Clin Cancer Res; 2022 May; 28(10):2110-2117. PubMed ID: 35254400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of the chromosome 11 mucin genes in colorectal cancer.
    Sylvester PA; Myerscough N; Warren BF; Carlstedt I; Corfield AP; Durdey P; Thomas MG
    J Pathol; 2001 Oct; 195(3):327-35. PubMed ID: 11673830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study.
    Murakami T; Akazawa Y; Yatagai N; Hiromoto T; Sasahara N; Saito T; Sakamoto N; Nagahara A; Yao T
    Diagn Pathol; 2018 Nov; 13(1):88. PubMed ID: 30458818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature.
    Kesari MV; Gaopande VL; Joshi AR; Babanagare SV; Gogate BP; Khadilkar AV
    Indian J Gastroenterol; 2015 Jan; 34(1):63-7. PubMed ID: 25731647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.